Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 6/2014

01-06-2014 | Original Article

Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood

Authors: Ferdousi Chowdhury, Holger N. Lode, Mark S. Cragg, Martin J. Glennie, Juliet C. Gray

Published in: Cancer Immunology, Immunotherapy | Issue 6/2014

Login to get access

Abstract

Neuroblastoma, a childhood tumour of neuroectodermal origin, accounts for 15 % of paediatric cancer deaths, which is often metastatic at diagnosis and despite aggressive therapies, it has poor long-term prognosis with high risk of recurrence. Monoclonal antibody (mAb) therapy targeting GD2, a disialoganglioside expressed on neuroblastoma, has shown promise in recent trials with natural killer cell (NK)-mediated antibody-dependent cellular cytotoxicity (ADCC) thought to be central to efficacy, although other immune effectors may be important. To further enhance therapy, immunomonitoring of patients is essential to elucidate the in vivo mechanisms of action and provides surrogate end points of efficacy for future clinical trials. Our aim was to establish a ‘real-time’ ex vivo whole-blood (WB) immunomonitoring strategy to perform within the logistical constraints such as limited sample volumes, anticoagulant effects, sample stability and shipping time. A fluorescent dye release assay measuring target cell lysis was coupled with flow cytometry to monitor specific effector response. Significant target cell lysis with anti-GD2 antibody (p < 0.05) was abrogated following NK depletion. NK up-regulation of CD107a and CD69 positively correlated with target cell lysis (r > 0.6). The ADCC activity of WB correlated with peripheral blood mononuclear cells (r > 0.95), although WB showed overall greater target cell lysis attributed to the combination of NK-mediated ADCC, CD16+ granulocyte degranulation and complement-dependent cytotoxicity. Response was maintained in heparinised samples stored for 24 h at room temperature, but not 4 °C. Critically, the assay showed good reproducibility (mean % CV < 6.4) and was successfully applied to primary neuroblastoma samples. As such, WB provides a resourceful analysis of multiple mechanisms for efficient end point monitoring to correlate immune modulation with clinical outcome.
Literature
1.
go back to reference Anegón I, Cuturi MC, Trinchieri G, Perussia B (1988) Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 167(2):452–472PubMedCrossRef Anegón I, Cuturi MC, Trinchieri G, Perussia B (1988) Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 167(2):452–472PubMedCrossRef
2.
4.
go back to reference Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27(7):1007–1013PubMedCentralPubMedCrossRef Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27(7):1007–1013PubMedCentralPubMedCrossRef
5.
go back to reference Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK (1998) Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 4:2135PubMed Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK (1998) Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 4:2135PubMed
6.
go back to reference Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334PubMedCentralPubMedCrossRef Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334PubMedCentralPubMedCrossRef
7.
go back to reference Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Landenstein R, Lode HN (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42(11):1311–1319PubMedCrossRef Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Landenstein R, Lode HN (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42(11):1311–1319PubMedCrossRef
8.
go back to reference Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11(11):805–812PubMedCentralPubMedCrossRef Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11(11):805–812PubMedCentralPubMedCrossRef
9.
go back to reference Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ (2012) Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol 32(4):855–865PubMedCrossRef Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ (2012) Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol 32(4):855–865PubMedCrossRef
10.
go back to reference Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8(6):1131–1135PubMedCentralPubMed Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8(6):1131–1135PubMedCentralPubMed
11.
go back to reference Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112:4170–4177PubMedCrossRef Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112:4170–4177PubMedCrossRef
12.
go back to reference Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172(5):2731–2738PubMedCrossRef Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172(5):2731–2738PubMedCrossRef
13.
go back to reference Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R (2006) FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24(18):2885–2890PubMedCrossRef Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R (2006) FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24(18):2885–2890PubMedCrossRef
14.
go back to reference Wang SY, Racila E, Taylor RP, Weiner GJ (2008) NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111(3):1456–1463PubMedCentralPubMedCrossRef Wang SY, Racila E, Taylor RP, Weiner GJ (2008) NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111(3):1456–1463PubMedCentralPubMedCrossRef
15.
go back to reference van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 12(13):4027–4035PubMedCrossRef van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 12(13):4027–4035PubMedCrossRef
16.
go back to reference Albanesi M, Mancardi DA, Jönsson F, Iannascoli B, Fiette L, Di Santo JP, Lowell CA, Bruhns P (2013) Neutrophils mediate antibody-induced anti-tumor effects in mice. Blood 122(18):3160–3164PubMedCrossRef Albanesi M, Mancardi DA, Jönsson F, Iannascoli B, Fiette L, Di Santo JP, Lowell CA, Bruhns P (2013) Neutrophils mediate antibody-induced anti-tumor effects in mice. Blood 122(18):3160–3164PubMedCrossRef
17.
go back to reference Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118(12):3347–3349PubMedCentralPubMedCrossRef Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118(12):3347–3349PubMedCentralPubMedCrossRef
18.
go back to reference Williams EL, Dunn SN, James S, Johnson PW, Cragg MS, Glennie MJ, Gray JC (2013) Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res 19(13):3545–3555PubMedCentralPubMedCrossRef Williams EL, Dunn SN, James S, Johnson PW, Cragg MS, Glennie MJ, Gray JC (2013) Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res 19(13):3545–3555PubMedCentralPubMedCrossRef
19.
go back to reference Chowdhury F, Williams AP (2009) From research to regulated: challenges in transferring methods. Bioanalysis 1(2):285–291PubMedCrossRef Chowdhury F, Williams AP (2009) From research to regulated: challenges in transferring methods. Bioanalysis 1(2):285–291PubMedCrossRef
Metadata
Title
Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood
Authors
Ferdousi Chowdhury
Holger N. Lode
Mark S. Cragg
Martin J. Glennie
Juliet C. Gray
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 6/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1534-y

Other articles of this Issue 6/2014

Cancer Immunology, Immunotherapy 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine